 |
PDBsum entry 6bwk
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
Nat Commun
9:2422
(2018)
|
|
PubMed id:
|
|
|
|
|
| |
|
Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis.
|
|
E.J.Petrie,
J.J.Sandow,
A.V.Jacobsen,
B.J.Smith,
M.D.W.Griffin,
I.S.Lucet,
W.Dai,
S.N.Young,
M.C.Tanzer,
A.Wardak,
L.Y.Liang,
A.D.Cowan,
J.M.Hildebrand,
W.J.A.Kersten,
G.Lessene,
J.Silke,
P.E.Czabotar,
A.I.Webb,
J.M.Murphy.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Necroptotic cell death is mediated by the most terminal known effector of the
pathway, MLKL. Precisely how phosphorylation of the MLKL pseudokinase domain
activation loop by the upstream kinase, RIPK3, induces unmasking of the
N-terminal executioner four-helix bundle (4HB) domain of MLKL, higher-order
assemblies, and permeabilization of plasma membranes remains poorly understood.
Here, we reveal the existence of a basal monomeric MLKL conformer present in
human cells prior to exposure to a necroptotic stimulus. Following activation,
toggling within the MLKL pseudokinase domain promotes 4HB domain disengagement
from the pseudokinase domain αC helix and pseudocatalytic loop, to enable
formation of a necroptosis-inducing tetramer. In contrast to mouse MLKL,
substitution of RIPK3 substrate sites in the human MLKL pseudokinase domain
completely abrogated necroptotic signaling. Therefore, while the pseudokinase
domains of mouse and human MLKL function as molecular switches to control MLKL
activation, the underlying mechanism differs between species.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |